Flex Point Security Aquestive Therapeutics (NASDAQ:AQST) is quickly approaching a key topline data readout for the Anaphylm (epinephrine) sublingual film that is slated for Q1 of this year. The company announced in December that they have commenced the first patient dosing in its Phase III pivotal study evaluating Anaphylm’s pharmacokinetics “PK” and pharmacodynamics “PD”. If the data is positive, Anaphylm would be heading towards a possible NDA in 2024 as a groundbreaking oral epinephrine candidate in  ...